SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Lock-Up Expiration Hell Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (513)11/23/2001 10:10:18 AM
From: scaram(o)uche  Read Replies (1) of 1005
 
>> Would they be looking for each other,
or are they competing? There seems to be some overlap in the programs. <<

I'm looking at it as a "Medinox acquires ALTH and ALTH's management finds something else to do" fantasy.

Note, however, that the abstract that I found shows a *downside*.

Competing? I haven't looked at the ALTH pipeline beyond RSR13. But, the "allosteric modification of hemoglobin" program would appear to have sufficient overlap/complementation. There are other potential overlaps.... peroxynitrite toxicities, etc. Nobody knows the problems associated with NO depletion like ex-Somatogen types.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News